- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01280734
Investigation of Melatonin and Zolpidem Effect on Postural Instability in Healthy Adult Subjects
December 11, 2011 updated by: Neurim Pharmaceuticals Ltd.
Randomised, Double-blind, 3-way Crossover, Single Dose, Placebo-controlled Study Investigating the Effect on Postural Instability of Melatonin and Zolpidem in Healthy Adult Subjects Aged of 55 to 64 Years.
This is a randomised, double-blind, 3-way crossover, single dose, placebo-controlled study investigating the effect on night time awakening body sway of melatonin and zolpidem in healthy adult subjects aged of 55 to 64 years.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Rouffach, France
- Forenap
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
55 years to 64 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The subject must have signed an informed consent form.
- The subject is a healthy man or woman. Women of child bearing potential or within two years of menopause must have negative urine pregnancy test at screening and use contraceptives as indicated in the protocol.
- The subject is 55 to 64 years of age (extremes included).
- The subject has a BMI >19 kg/m2 and < 30 kg/m2 at the Screening Visit.
- The subject has a normal circadian rhythm, defined as a person who usually wakes between 06:00 and 09:00 and goes to sleep between 21:00 and 24:00.
- The subject is, in the opinion of the investigator, generally healthy based on assessment of medical history and examination at screening
- The subject is affiliated with, or beneficiary of a social security system.
Major Exclusion Criteria:
- The subject has taken disallowed medication within 1 week prior to the first dose of IMP (or within 5 half-lives prior to admission for any medication ingested, whichever is longer). Disallowed medication is any prescribed medication or over-the-counter (OTC) medication as well as any herbal medicine known to interfere with the metabolic CYP pathways, such as St. John's Wort (except for hormonal contraceptives or hormonal substitution therapy). Subjects who have taken any non-prescribed systemic or topical medication may still be entered into the study if, in the opinion of the investigator, the medication will not interfere with the study procedures, study results, or compromise safety.
- The subject weighs >136 kg.
- The subject cannot stand erect and unsupported for more than 2 to 3 minutes or loses balance when standing on a fixed surface with eyes opened.
- The subject has an excessive consumption of beverages on xanthine bases (more than 4 cups or glasses daily).
- The subject has a presence or history of alcohol abuse defined as alcohol consumption greater than 21 units per week for men and greater than 14 units per week for women; or a presence or history of drug abuse within the last 6 months, or a history of substance abuse deemed relevant by the investigator.
- The subject has taken any investigational products including these IMPs (zolpidem, melatonin) within 3 months prior to admission on Day 1.
- The subject has taken these IMPs earlier in this clinical study.
- The subject has known hypersensitivity to the melatonin, zolpidem or their excipients.
- The subject has a history of severe drug allergy or hypersensitivity.
- The subject is pregnant or breastfeeding.
- The subject has a presence or history of sleep disorder, fainting, cardiovascular diseases, carotid sinus syndrome, relevant dizziness or arrhythmia.
- The subject has a history of or presence of any clinically relevant immunological, cardiovascular, pulmonary, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological, systemic, ocular or psychiatric or infectious disease or other major disorder, or sign of acute illness.
- The subject has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin, which has not been in remission for at least 5 years before the first dose of IMP.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
One tablet or encapsulated tablet at 23:00
|
ACTIVE_COMPARATOR: Melatonin
Circadin(R) 2 mg tablet 2 hours at 23:00
|
One 2 mg tablet at 23:00
|
ACTIVE_COMPARATOR: Zolpidem
Stilnox (R) 10 mg tablet at 23:00
|
One 10 mg encapsulated tablet at 23:00
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Body sway
Time Frame: 4 hours post IMP adminstration
|
4 hours post IMP adminstration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Body Sway
Time Frame: 1.5 hours post administration
|
1.5 hours post administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2011
Primary Completion (ACTUAL)
April 1, 2011
Study Completion (ACTUAL)
May 1, 2011
Study Registration Dates
First Submitted
January 19, 2011
First Submitted That Met QC Criteria
January 20, 2011
First Posted (ESTIMATE)
January 21, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
December 13, 2011
Last Update Submitted That Met QC Criteria
December 11, 2011
Last Verified
December 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Neurim-PIS1
- 2010-023745-29 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postural Instability
-
Akdeniz UniversityNot yet recruitingMusculoskeletal Pain | Spinal Instability | Postural KyphosisTurkey
-
Bezmialem Vakif UniversityCompletedGait Disorders in Children | Balance | Postural Stability | Postural Control | Femoral AnteversionTurkey
-
Kafrelsheikh UniversityCompleted
-
Baltimore VA Medical CenterCompleted
-
Escoles Universitaries GimbernatCompleted
-
Liberty UniversityNational Academy of Sports MedicineCompletedPostural; DefectUnited States
-
University of LausanneCompletedPostural ControlSwitzerland
-
East Tennessee State UniversityCompletedPostural BalanceUnited States
-
University Hospital HeidelbergCompleted
-
William Beaumont Army Medical CenterUnknownLateral Ankle InstabilityUnited States
Clinical Trials on Circadin (R) 2 mg
-
Neurim Pharmaceuticals Ltd.Completed
-
LG Life SciencesCompletedHypertension | HyperlipidemiaKorea, Republic of
-
University of California, Los AngelesNational Institute of Allergy and Infectious Diseases (NIAID)CompletedRespiratory Tract Infections | Influenza | VaccinesUnited States
-
Oslo University HospitalTakeda Nycomed; Sykehuset Asker og BaerumCompleted
-
Neurim Pharmaceuticals Ltd.CompletedSleep DisordersUnited States, Netherlands, United Kingdom, Finland, France
-
Tel-Aviv Sourasky Medical CenterUnknown
-
The Lymphoma Academic Research OrganisationFrench Innovative Leukemia OrganisationCompleted
-
Firstkind LtdWithdrawn
-
Instituto de Investigación Hospital Universitario...CompletedCoronavirus Infection | SARS-CoV 2 | Covid19Spain
-
Jiangsu HengRui Medicine Co., Ltd.Completed